Adverse effects of immunotherapies for multiple sclerosis : A network meta-analysis by I. Tramacere et al.
Cochrane Database of Systematic Reviews
Adverse effects of immunotherapies for multiple sclerosis: a
network meta-analysis (Protocol)
Tramacere I, Benedetti MD, Capobussi M, Castellini G, Citterio A, Del Giovane C, Frau S, Gonzalez-
Lorenzo M, La Mantia L, Moja L, Nuzzo S, Filippini G
Tramacere I, Benedetti MD, Capobussi M, Castellini G, Citterio A, Del Giovane C, Frau S, Gonzalez-Lorenzo M, La Mantia L, Moja L, Nuzzo S,
Filippini G.
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD012186.
DOI: 10.1002/14651858.CD012186.
www.cochranelibrary.com
Adverse effects of immunotherapies for multiple sclerosis: a networkmeta-analysis (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iAdverse effects of immunotherapies for multiple sclerosis: a network meta-analysis (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Adverse effects of immunotherapies for multiple sclerosis: a
network meta-analysis
Irene Tramacere1,Maria Donata Benedetti2,MatteoCapobussi3 , Greta Castellini3,4, Antonietta Citterio5, Cinzia DelGiovane6 , Serena
Frau7 , Marien Gonzalez-Lorenzo3 , Loredana La Mantia8 , Lorenzo Moja3 ,9, Sara Nuzzo10, Graziella Filippini11
1Neuroepidemiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. 2UOC Neurologia B - Policlinico
Borgo Roma, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. 3Department of Biomedical Sciences for Health, University of
Milan, Milan, Italy. 4Unit of Clinical Epidemiology, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy. 5Scientific Direction, IRCCS
National Neurological Institute C. Mondino, Pavia, Italy. 6Italian Cochrane Centre, Department of Diagnostic, Clinical and Public
Health Medicine, University of Modena and Reggio Emilia, Modena, Italy. 7Brighton and Hove, UK. 8Unit of Neurorehabilitation
- Multiple Sclerosis Center, IRCCS. Santa Maria Nascente - Fondazione Don Gnocchi, Milan, Italy. 9Clinical Epidemiology Unit,
IRCCS Galeazzi Orthopaedic Institute, Milan, Italy. 10Fondazione IRCCS. Istituto Neurologico Carlo Besta, Milan, Italy. 11Scientific
Direction, Fondazione IRCCS. Istituto Neurologico Carlo Besta, Milan, Italy
Contact address: Irene Tramacere, Neuroepidemiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Giovanni
Celoria, 11, Milan, 20133, Italy. irene.tramacere@istituto-besta.it.
Editorial group: Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group.
Publication status and date: New, published in Issue 5, 2016.
Citation: Tramacere I, Benedetti MD, Capobussi M, Castellini G, Citterio A, Del Giovane C, Frau S, Gonzalez-Lorenzo M, La
Mantia L, Moja L, Nuzzo S, Filippini G. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. Cochrane
Database of Systematic Reviews 2016, Issue 5. Art. No.: CD012186. DOI: 10.1002/14651858.CD012186.
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To compare adverse effects of immunotherapies for people with multiple sclerosis (MS) or clinically isolated syndrome (CIS), and to
rank these treatments according to their relative risks of adverse effects.
B A C K G R O U N D
Description of the condition
General view
Multiple sclerosis (MS) is a chronic disease of the central nervous
system (CNS) that affects mainly young adults - two to three
times more frequently women than men - and causes significant
disability two or more decades after onset. Neurological signs and
symptoms reflect dissemination of inflammatory lesions (plaques)
through different areas of the CNS, including optic nerve, spinal
cord, brainstem, cerebellum and cerebral hemispheres. The initial
clinical course is characterised by exacerbations and remissions,
with complete or incomplete recovery reported in more than 85%
of cases, and a primary progressive course noted in 10% to 15%
(Compston 2008). Disease severity is variable, with some patients
accumulating a low degree of disability during their lifetime, and
others experiencing within a short time a rapidly aggressive clinical
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course.
Pathogenesis
The pathological hallmark of MS consists of focal inflammation,
demyelination, axonal degeneration and gliosis, interplaying in
variable degrees over different stages of the disease. It is still de-
bated whether inflammation, clinically expressed by relapses, and
neurodegeneration, which causes progression of disability, are se-
quential or independent processes (Compston 2008; Hutchinson
2015; Louapre 2015; Weinshenker 1989). A heterogeneous pop-
ulation of mediators of the immune system, such as T cells, B
cells, macrophages, cytokines, chemokines and complement, is in-
volved in inflammatory demyelinating processes, while activation
of microglia, chronic oxidative stress, mitochondrial damage in
axons and age-related iron accumulation drive neurodegeneration
(Brück 2005; Friese 2014).
Etiology
Multiple sclerosis is believed to be an immune-mediated disease
triggered by environmental factors in genetically susceptible in-
dividuals (Compston 2008). Epstein-Barr virus infection, low vi-
tamin D levels and smoking are the environmental factors most
consistently associated with this disease (Ascherio 2013). The ge-
netic contribution to MS development is not yet completely elu-
cidated, although to date more than 100 loci have been associated
with MS genetic susceptibility, many related to immune function
genes, and theHLA-DR1 locus within themajor histocompatibil-
ity complex (MHC) has shown the strongest effect (Hollenbach
2015; Simpson 2015). The frequency of MS increases with in-
creasing latitude in both northern and southern hemispheres, with
incidence estimates ranging from 1 to 10/100,000 population per
year in different places in the world, and with Europe and North
America expressing highest prevalence of the disease (> 100 cases
per 100,000 population) (Atlas of MS 2013).
Phenotype classification
Clinical subtypes of MS defined in 1996 by a consensus paper in-
clude relapsing-remittingMS (RRMS), secondary-progressive MS
(SPMS), primary-progressive MS (PPMS) and progressive-relaps-
ingMS (PRMS) (Lublin 1996). A recent revision of this classifica-
tion incorporates disease activity on the basis of clinical relapse or
imaging findings and progression of disability as disease course de-
scriptors, eliminating the prior category of PRMS (Lublin 2014).
This revision also includes clinically isolated syndrome (CIS), al-
ready defined by McDonald diagnostic criteria (2001) as the first
clinical presentation ofMS in which the criterion of dissemination
over time has not yet been fulfilled (Lublin 2014).
Diagnostic criteria
Over past decades, MSwas clinically diagnosed when two separate
attacks (dissemination in time - DIT) were observed in at least
two different sites (dissemination in space - DIS) of the CNS, with
any better explanation excluded (Poser 1983). In the McDonald
diagnostic criteria of 2001 and 2005, magnetic resonance imaging
(MRI) was incorporated to define DIS and DIT, allowing earlier
diagnosis of MS (McDonald 2001; Polman 2005). According to
the most recent revision (Polman 2011), MS may be diagnosed
with a single clinical episode when a single brain MRI shows both
asymptomatic gadolinium-enhancing and non-enhancing lesions.
Clinical course
Natural history studies have reported a transition to a secondary
progressive course in some 80% of RRMS patients within 20 to
25 years of onset when neurodegenerative processes prevailed over
inflammatory changes, with similar age at onset of progression
and disease evolution during the progressive phase in SPMS and
PPMS (Confavreux 2006; Kremenchutzky 2006; Scalfari 2014;
Weinshenker 1989). Progressive phase delay, prevention and at-
tenuation are key therapeutic targets in MS (Scalfari 2010). Me-
dian survival from disease onset may reach five decades, with age
at death beyond 75 and life expectancy reduced by seven to 14
years compared with the general population (Scalfari 2013).
Therapy
Although neuroprotective drugs against axonal loss and degenera-
tion are not available, several drugs have been tested and approved
over the past 20 years for RRMS treatment on the basis of the
immune-mediated mechanism of the disease in an attempt to re-
duce active inflammatory manifestations (relapses) with the goal
of delaying conversion of CIS in definitive MS or the transition
to a secondary progressive course. No treatment for PPMS has
actually been approved.
Critical points in recentMS randomised clinical trials (RCTs) con-
sist of inclusion of people at earlier stages of disease with lower dis-
ease activity comparedwith historical RCTs, limited use of placebo
for ethical reasons and short trial duration to demonstrate drug
efficacy, so that safety outcomes become manifest in postmarket-
ing observations.
Description of the intervention
We will consider all immunotherapies that are used, whether ap-
proved or off-label, or are currently under marketing authorisation
or investigation for people with MS or CIS.
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Approved
Beta interferons (Betaferon/Betaseron®; Extavia®; Rebif®;
Avonex®) and glatiramer acetate (Copaxone® )were the first agents
approved by national regulatory agencies (EMEA 1997; EMEA
1998; EMEA 2002; FDA 1993; FDA 1996; FDA 2002; FDA
2003). These medications are administered subcutaneously, ex-
cept for beta interferon 1a (Avonex®), which is administered by
intramuscular injection.
Mitoxantrone (Novantrone®) was approved in 2000 in the USA
(FDA 2000), Europe and other countries for treatment of patients
with RRMS and progressive MS. A short intravenous infusion is
given every three months.
Natalizumab (Tysabri®), approved for RRMS (EMA 2006; FDA
2006), is administered by intravenous infusion at a dose of 300
mg every four weeks.
Fingolimod (Gilenya®), approved for RRMS (EMA 2011; FDA
2010), is given as a 0.5 mg oral dose once daily.
Teriflunomide (Aubagio®), approved for RRMS (EMA 2013a;
FDA 2012), is given as a 7 or 14 mg oral dose once daily.
Dimethyl fumarate (Tecfidera®), approved for RRMS (EMA
2014a; FDA 2013a), is given as a 240 mg oral dose twice daily.
Alemtuzumab (Lemtrada®), approved for RRMS (EMA 2013b;
FDA 2014a), is administered intravenously in two annual treat-
ment courses - the first as a 12 mg dose daily on five consecutive
days (60 mg total dose), and the second, 12 months later, on three
consecutive days (36 mg total dose).
Peginterferon beta-1a (Plegridy®), approved for RRMS (EMA
2014b; FDA 2014b), is given by subcutaneous injection at a dose
of 125 micrograms every 14 days.
Cladribine (Movectro®) was approved in Russia and Australia for
RRMS in 2010 (Murphy 2010), but it was not approved by the
European Medicines Agency (EMA) (EMA 2010) and the Food
and Drug Administration (FDA) in 2011 because of a suspected
increase in cancer risk that has not been confirmed by results of a
meta-analysis of trials (Pakpoor 2015).Cladribinewas investigated
in two trials (Giovannoni 2010; Leist 2014): It was given as tablets
at a cumulative dose of 3.5 mg/kg (0.875 mg/kg per course, given
over four or five consecutive days, for two courses during the first
48 weeks, then two courses of cladribine 0.875 mg/kg during the
second 48 weeks) or 5.25 mg/kg (0.875 mg/kg per course for four
courses during the first 48 weeks, then two courses during the
second 48 weeks).
Used off-label
Azathioprine has been used for the treatment of patients with MS
in many countries on the basis of placebo-controlled RCTs pub-
lishedmore than two decades ago. However, since beta interferons
were approved, azathioprine is no longer recommended as first-
line therapy (Goodin 2002). It is taken orally daily as a 2 or 3 mg/
kg tablet.
Intravenous immunoglobulins have been used for people with se-
vere and frequent relapses, for whom other treatments were con-
traindicated (Association of British Neurologists 2005).
Rituximab has been evaluated in two trials (Hauser 2008; Hawker
2009). In one trial that included participants with RRMS (Hauser
2008), study authors found beneficial effects on clinical andMRI-
visualised disease activity that were maintained over 48 weeks; in
the other trial of participants with PPMS (Hawker 2009), study
authors found no significant effects on time to confirmed disease
progression. This drug is administered intravenously.
Methotrexate is commonly prescribed in general practice to con-
trol autoimmune diseases, including neuromyelitis optica; it has
been used since 1996 for MS (Goodkin 1996), mainly progressive
MS; it is taken orally as 7.5 mg weekly (with 1 mg daily folic acid
supplementation) (Gray 2004).
Cyclophosphamide is an alkylating agent of DNA used for the
treatment of patients with autoimmune disorders. It has been ad-
ministered to patients with MS since 1991 by various schedules as
1 g i.v. over three days, or 400 to 500 mg/d i.v. over five days alone
or along with adrenocorticotropin hormone (ACTH) or plasma
exchange, or it has been given orally at 2 mg/kg/d (La Mantia
2007).
Long-term corticosteroids have been proposed for the treatment
of patients with MS since 1961, with controversial results. They
have been administered by different schedules as pulsed periodic
high-dose methylprednisolone or oral continuous low-dose pred-
nisolone (Ciccone 2008).
Currently under marketing authorisation or
investigation
Daclizumab (Zenapax®) is administered by subcutaneous or in-
travenous injection. Review processes by EMA and FDA are on-
going.
Laquinimod (Nerventra®)was investigated in twophase 3 trials for
treatment of patients with RRMS (Comi 2012; Vollmer 2014). An
oral dose of 0.6 mg daily has been used in trials. This drug received
a negative response from the EMA for use in treating patients with
RRMS (EMA 2014c). Additional studies on laquinimod in people
with RRMS are ongoing.
Ocrelizumab is under development for treatment of patients with
RRMS and PPMS, and clinical trials are ongoing (Kappos 2011).
It is administered by intravenous injection.
How the intervention might work
The harm profile of an intervention is strictly related to its mech-
anism of action, its modality of administration and pharmacoki-
netic, pharmacodynamic and possibly pharmacogenetic aspects of
drug response (Goodman 2006).
According to the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for
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Human Use (ICH 2015), adverse events (AEs) are classified in
terms of system organ class (SOC), that is, by identifying the
anatomical or physiological system affected by the AE itself.
Immunotherapies forMS belong to different pharmacological cat-
egories, have different modalities of administration (by intramus-
cular or subcutaneous injection, by infusion or bymouth) andhave
different metabolism; although all target the immune system, they
are characterised by different effects, as follows: (1) immunomod-
ulation (interferon beta-1b, interferon beta-1a (Avonex, Rebif ),
glatiramer acetate, pegylated interferon beta-1a, immunoglobu-
lins, dimethyl fumarate, laquinimod); (2) systemic immunosup-
pression, inducing a reduction in activation or efficacy of the
immune system through cytostatic or cytotoxic effects (mitox-
antrone, methotrexate, cyclophosphamide, long-term corticos-
teroids, cladribine, azathioprine, teriflunomide); and (3) selective
immunosuppression, as with monoclonal antibodies or biologi-
cal agents directed towards exactly defined antigens (natalizumab,
fingolimod, alemtuzumab, daclizumab, rituximab, ocrelizumab).
These aspects must be considered when the safety profile of a drug
is determined because safety is usually a consequence of the drug’s
primary pharmacological effect.
We might classify main types and the etiopathogenesis of AEs of
MS immunotherapies according to the Medical Dictionary for
Regulatory Activities System Organ Classes (MedDRA SOC), as
follows.
• Immune system disorders. All immunotherapies may cause
acute or delayed systemic reactions due to allergic response,
anaphylaxis, autoimmune disorder, cytokine release syndrome
and serum sickness. Such reactions occur in particular during
monoclonal antibody treatment (Lycke 2015) but also with
immunomodulating agents, such as interferons. The exact
process of flu-like interferon syndrome is poorly understood but
probably is related to increased endogenous pyrogens such as
interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α)
(Martìnez-Càceres 1998). Autoimmune diseases such as
thyroiditis, psoriasis and rheumatoid arthritis are more frequent
in people treated with immunomodulatory or
immunosuppressive drugs than in naive patients (Chouhfeh
2015).
• Blood and lymphatic system disorders. Cytostatic effects or
selective antagonism versus critical cell antigens might cause
complete or partial myelodepression, or lymphopenia. This latter
AE occurs, for example, in fingolimod-treated people, as the
result of prevention of egress from secondary lymphoid tissues or
following use of alemtuzumab, which selectively causes depletion
of T and B lymphocytes. The mechanisms of these AEs during
immunomodulating therapies (interferons, dimethyl fumarate)
remain uncertain.
• Infections and infestations. These might occur during
immunosuppressive therapies that impair the immune system
and induce immunosurveillance depression. Opportunistic
infection such as progressive multi-focal leukoencephalopathy
(PML) in people treated with natalizumab seems to be due to
inhibition of effector T-cell trafficking from blood to CNS,
which might favour local John Cunningham virus (JCV)
replication (Van Assche 2005). PML has also been reported in
people treated with fingolimod or dimethyl fumarate, probably
resulting from similar causes. Other opportunistic infections
such as herpes virus reactivation and tuberculosis are associated
with immunosuppressive or immunomodulatory therapies
(Williamson 2015).
• Pregnancy, puerperium and perinatal conditions. Pregnancy
and foetal damage have been reported with all therapies,
although with different severity of harm or risk for reproductive
potential and pregnancy category rating (Federal Register 2015).
They are probably related to pharmacological effects on DNA
and RNA replication (Amato 2015).
• Neoplasms benign, malignant and unspecified. The relative
carcinogenicity of each agent (not described until now for
immunomodulating agents) is not well understood. Different
types of tumours have been found to be related to use of selective
or non-selective immunosuppressive drugs such as fingolimod,
mitoxantrone and azathioprine, which have been associated with
risk of skin carcinoma, leukaemia and myelodysplastic syndrome,
respectively (Casetta 2007; Martinelli-Boneschi 2005).
AEs such as hepatic disorders are common to all types of drugs;
others seem to be strictly related to a specific compound. Fin-
golimod causes transient activation of sphingosine-1-phosphate
receptor 1 (S1P1) in atrial myocytes, which is associated with a
transient reduction in heart rate, while lung hyperreactivity lead-
ing to bronchospasms and airway constriction ismediated by S1P1
and sphingosine-1-phosphate receptor 3 (S1P3) activation. Alem-
tuzumab treatment is associated with risk of secondary autoimmu-
nity due to reconstitution of the lymphocyte repertoire. Dimethyl
fumarate-treated people have experienced flushing and gastroin-
testinal problems, although the causes of these events remain un-
certain (Bomprezzi 2015).
Many of these AEs are known and expected on the basis of a
drug’s mechanism of action and pharmacodynamic aspects; other
reactions remain of uncertain origin or appear during long-term
monitoring of people. Familiarity with the safety profile of each
drug is critical for identification of potential mitigation strategies
(Farber 2015).
Why it is important to do this review
Although consensus indicates that immunotherapies for people
with MS may decrease disease activity, uncertainty regarding their
relative safety remains. Systematic assessments have not been per-
formed to compare short-, medium- and long-term adverse effects
of each immunotherapy versus the others.
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O B J E C T I V E S
To compare adverse effects of immunotherapies for people with
multiple sclerosis (MS) or clinically isolated syndrome (CIS), and
to rank these treatments according to their relative risks of adverse
effects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all phase 2 and 3 RCTs that examined one or
more of the agents used in MS or CIS and compared them versus
placebo or another active agent. We will exclude RCTs in which a
drug regimen was compared with a different regimen of the same
drug without another active agent or placebo as a control arm.
Types of participants
We will include participants 18 years of age or older with a di-
agnosis of MS or CIS according to any accepted diagnostic crite-
ria (Lublin 1996; McDonald 2001; Polman 2005; Polman 2011;
Poser 1983). We will include all participants regardless of sex, de-
gree of disability or disease duration.
Types of interventions
We will include the following immunotherapies (even if they are
not licensed in any country) used as monotherapies (i.e. we will
exclude combination treatments).
• Interferon beta-1b.
• Interferon beta-1a (Avonex, Rebif ).
• Glatiramer acetate.
• Mitoxantrone.
• Natalizumab.
• Fingolimod.
• Teriflunomide.
• Dimethyl fumarate.
• Alemtuzumab.
• Pegylated interferon beta-1a.
• Cladribine.
• Azathioprine.
• Immunoglobulins.
• Rituximab.
• Daclizumab.
• Laquinimod.
• Ocrelizumab.
• Methotrexate.
• Cyclophosphamide.
• Long-term corticosteroids.
Wewill include regimens as defined inprimary studies, irrespective
of their dose and treatment duration.
Types of outcome measures
Primary outcomes
We will estimate the relative risks of adverse effects at longest
follow-up of competing interventions according to the following
primary outcomes.
• Number of participants with any (one or more) serious
adverse events (SAEs).
• Number of withdrawals due to adverse events (AEs).
We will adopt the following standard definitions of AEs and SAEs:
An adverse event is an adverse outcome that occurs while a patient
is taking a drug but is not (or is not necessarily) attributable to the
drug taken; serious adverse events are adverse events that occur at
any dose and result in death or life-threatening events, require-
ment for hospitalisation or prolongation of existing hospitalisa-
tion, persistent or significant disability or congenital anomalies,
or are considered medically important (ICH 2015).
Secondary outcomes
We will estimate the relative risks of adverse effects at longest fol-
low-up of competing interventions according to the following sec-
ondary outcomes, as classified by the Medical Dictionary for Reg-
ulatory Activities SystemOrgan Classes (MedDRA SOC) (version
18.0) (ICH 2015).
• Cardiac disorders (SAEs and AEs, separately).
• Infections and infestations (SAEs and AEs, separately).
• Administration site conditions (SAEs and AEs, separately).
• Nervous system disorders (SAEs and AEs, separately).
• Psychiatric disorders (SAEs and AEs, separately).
• Gastrointestinal disorders (SAEs and AEs, separately).
• Blood and lymphatic system disorders (SAEs and AEs,
separately).
• Hepatobiliary disorders (SAEs and AEs, separately).
• Immune system disorders (SAEs and AEs, separately).
• Pregnancy, puerperium and perinatal conditions.
• Deaths.
• Neoplasms.
We will express all outcomes for each SAE category as percentages
of participants with any (one or more) SAEs. We will express all
outcomes for each AE category as rates of AEs (i.e. number of AEs
divided by person-years of exposure). We expect that person-years
of exposure will not be available for each study;therefore, we will
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extract the duration of observation, so that this can be considered
as person-years of exposure.
Search methods for identification of studies
We will search for all possible comparisons among interventions
of interest and will apply no language restrictions to the search.
Electronic searches
The Trials Search Co-ordinator will search the Trials Register of
the Cochrane Multiple Sclerosis and Rare Diseases of the CNS
Group, which, among other sources, contains trials from:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (2016, most recent issue);
• MEDLINE (PubMed) (1966 to date);
• EMBASE (EMBASE.com) (1974 to date);
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (EBSCOhost) (1981 to date);
• Latin American and Caribbean Health Science Information
Database (LILACS) (Bireme) (1982 to date);
• ClinicalTrials.gov (www.clinicaltrials.gov); and
• World Health Organization (WHO) International Clinical
Trials Registry Platform (apps.who.int/trialsearch).
Information on the Trials Register or the ReviewGroup and details
of the search strategies used to identify trials can be found in
the ’Specialised Register’ section within the Cochrane Multiple
Sclerosis and Rare Diseases of the CNS Group module.
The keywords that will be used to search for trials for this review
are listed in Appendix 1.
Searching other resources
We will extend the search to other resources, including:
• search of FDA pre-marketing and post-marketing reports
providing safety data on all treatments included in this review (
www.fda.gov);
• search of EMA pre-marketing and post-marketing reports
providing safety data on all treatments included in this review (
www.ema.europa.eu); and
• search of Australian medicines regulatory authority (the
Therapeutic Goods Administration - TGA) pre-marketing and
post-marketing reports providing safety data on all treatments
included in this review (www.tga.gov.au).
Data collection and analysis
Selection of studies
We will use the search strategy described above to obtain titles
and abstracts of studies that may be relevant to the review. Two
teams of two review authors each (GC and SF;MGL andMC)will
independently screen titles and abstracts and will discard studies
that are not applicable; however, we will at first retain studies and
reviews that might include relevant data or information on trials.
Two teams of two review authors each (GC and SF; MGL and
MC) will independently assess the retrieved abstracts and, when
necessary, the full text of these studies to determine which studies
satisfy the inclusion criteria. We will compare multiple reports of
the same study and will use the most comprehensive report. We
will not link together multiple publications of the primary study
that did not report AEs, and we will exclude true duplicates. We
will resolve discrepancies in judgement by discussion with a third
review author (IT).
Data extraction and management
Two review authors (IT and SN) will independently extract data
using a pre-defined data extraction form within an Excel spread-
sheet. We will resolve disagreements by discussion with a third
review author (GF).
Outcome data
We will extract from each included study the number of partici-
pants who:
• had any SAE;
• withdrew because of any AE;
• experienced any specific AE or SAE according to the
MedDRA SOC (ICH 2015), as defined in the Types of outcome
measures section;
• were randomised; and
• took one or more doses of treatment.
We will extract arm-level data when possible. When arm-level data
are not available, we will extract effect sizes.
When data are not reported or are unclear in the primary studies,
we will consult reports from FDA, EMA and TGA.
Data on potential effect modifiers
We will extract from each included study data on the following
potential effect modifiers.
• Population: age (range), disease course (CIS, RRMS,
SPMS, PPMS and PRMS), disease duration for MS and time
since neurological event for CIS (mean if provided or median),
EDSS (mean), previous treatment with immunotherapies (no or
yes/possible).
• Study design: duration of follow-up.
• Intervention: dose, frequency or duration of treatment.
• Risk of bias: blinding of participants, blinding of outcome
assessors, incomplete outcome data.
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• Funding source.
Other data
We will extract from each included study data on the following
additional information.
• Study: first author or acronym, number of centres, year of
publication, recruitment period, publication type (full-text
publication, abstract publication, unpublished data).
• Study design: inclusion criteria, sequence generation,
allocation concealment, selective outcome reporting, early
termination of trial.
Assessment of risk of bias in included studies
We will assess the risk of bias of each included study by using the
criteria of The Cochrane Collaboration (Higgins 2011). These in-
clude random sequence generation, allocation concealment, blind-
ing of participants, blinding of outcome assessors, incomplete out-
come data and selective outcome reporting. Another potential risk
of bias involves the role of the sponsor. We will explicitly judge
the risk of bias of each study on the basis of each criterion and will
classify the study as having ’low’, ’high’, or ’unclear’ risk of bias.
We will judge incomplete outcome data as showing low risk of
bias when numbers and causes of dropouts are balanced (i.e. in the
absence of a significant difference) between arms and appear to be
unrelated to studied outcomes. We will judge selective outcome
reporting as showing low risk of bias when study results include
the three outcome categories relevant to the review, that is, SAEs,
AEs and withdrawals due to AEs.
To summarise the quality of the evidence, we will consider blind-
ing of participants, blinding of outcome assessors and incomplete
outcome data to classify each study as having low risk of bias when
we judge all of the selected criteria as having low risk of bias; high
risk of bias when we judge at least one criterion among those se-
lected as having high risk of bias; and moderate risk of bias in the
remaining cases.
We will assess characteristics associated with monitoring and re-
porting of adverse events by considering specific factors that may
have a large influence on adverse event data.Wewill evaluatemeth-
ods of monitoring and detecting adverse events in each primary
study: Did researchers actively monitor for adverse events, or did
they simply provide spontaneous reporting of adverse events that
arose? Did study authors define SAEs according to an accepted in-
ternational classification and report the number of SAEs? We will
report this information in an additional table called ’Assessment
of adverse event monitoring’.
Two teams of two review authors each (GC and SF; MGL and
MC) will assess the risk of bias of each study independently and
will resolve disagreements by discussion to reach consensus.
Measures of treatment effect
Relative treatment effects
We will estimate, through pairwise meta-analysis, the safety of
competing interventions by using the risk or rate ratio (RR) with
95% confidence intervals (95% CIs) for each outcome. We will
present results from network meta-analysis as summary relative
effect sizes (RR) with 95%CIs for each possible pair of treatments.
Relative treatment ranking
We will estimate ranking probabilities for all treatments at each
possible rank for each intervention for each outcome. We will
then determine a treatment hierarchy by using the surface under
the cumulative ranking curve (SUCRA) and mean ranks (Salanti
2011).
Unit of analysis issues
Cluster and cross-over trials have not been carried out to evaluate
immunotherapies for the treatment of people with MS or CIS.
Studies with multiple treatment groups
For multi-arm trials, the intervention groups of relevance will be
those that could be included in a pairwise comparison of inter-
vention groups, which, if investigated alone, would have met the
criteria for inclusion of studies in the review. For example, if we
identify a study comparing ’interferon beta versus natalizumab
versus interferonbeta plus natalizumab’, only one comparison (’in-
terferon beta vs natalizumab’) addresses the review objective, and
no comparison involving combination therapy does so. Thus, the
’interferon beta plus natalizumab’ therapy group is not relevant
to the review. However, if the study had compared ’interferon
beta-1b versus interferon beta-1a (Rebif ) versus interferon beta-1a
(Avonex)’, all three pairwise comparisons of interventions would
be relevant to the review. In this case, we would treat multi-arm
studies as multiple independent two-arm studies in pairwise meta-
analysis and would account for the correlation between effect sizes
in multi-arm studies through network meta-analysis.
We will explore whether safety of the agent is modulated by treat-
ment dose as follows. We will consider the network formed from
agents administered at different doses (so that each node in the
network represents treatment at a different dose). We will trans-
form any specific dose used for each agent into a unique unit of
measure - ’dose per week’. We will re-analyse the network and will
derive network meta-analysis estimates for each drug and dose.
If no important dose-effect relationship is found, we will convert
multi-arm trials involving the same agent at different doses ver-
sus a control treatment into a single arm by merging doses and
summing numbers of events and sample size. Conversely, we will
analyse separately different treatment doses with different effects.
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Dealing with missing data
A likely scenario for assessment of effects of missing data on AE
outcomes (i.e. rates of AEs) is not feasible, and on SAE outcomes
is nonsense (i.e. assuming that participants who contributed to
missing outcome data had an SAE); therefore, we will perform a
sensitivity analysis including only trials with low risk of attrition
bias and will discuss the extent to which missing data could alter
results/conclusions of the review.
Assessment of heterogeneity
Assessment of clinical heterogeneity within treatment
comparisons
To evaluate the presence of heterogeneity derived from different
characteristics of study participants, we will assess differences in
age, MS course, disease duration and EDSS across trials using
information reported in the ’Characteristics of included studies’
table.
Assessment of transitivity across treatment comparisons
We will evaluate the assumption of transitivity by comparing po-
tential effect modifiers as reported in the Data extraction and
management section, across different pairwise comparisons.
Assessment of reporting biases
Given that it is notmandatory for investigators to publish results of
clinical trials, it is difficult for review authors to obtain an estimate
of the number of unpublished trials on MS. We will evaluate the
possibility of reporting bias by creating contour-enhanced funnel
plots (Peters 2008), which show areas of statistical significance
and can help to distinguish reporting bias from other possible
reasons for asymmetry. Each study estimates the relative effects of
different interventions, so asymmetry in the funnel plot cannot
be judged. To account for this, we will use an adaptation of the
funnel plot by subtracting from each study-specific effect size the
mean derived by meta-analysis of the study-specific comparison
and will plot it against the study’s standard error (Chaimani 2012;
Chaimani 2013).We will employ the comparison-adjusted funnel
plot for all placebo-controlled trials and will point out that any
asymmetry in the plot indicates the presence of small study effects,
not necessarily reporting bias.
Data synthesis
Methods for direct treatment comparisons
Wewill perform conventional pairwise meta-analyses for each pri-
mary outcome using a random-effects model for each treatment
comparison with at least two studies (DerSimonian 1986).
Methods for indirect and mixed comparisons
We will perform network meta-analyses using random-effects
models within a frequentist setting assuming equal heterogene-
ity across all comparisons, and we will account for correlations
induced by multi-arm studies (Miladinovic 2014; Salanti 2012).
These models will enable us to estimate the probability that each
intervention will be at each possible rank for each outcome, given
the relative effect sizes as estimated in the network meta-analysis.
We will summarise the probabilities that a treatment will be at
each possible rank by using SUCRAs. By using the cluster analysis
technique, we will group treatments according to SUCRA values
and will present them in a plot. We will perform network meta-
analysis in Stata 13 using the ’mvmeta’ command and self pro-
grammed Stata routines (Chaimani 2013; Multiple-Treatments
Meta-analysis (MTM); White 2011; White 2012).
Subgroup analysis and investigation of heterogeneity
Assessment of statistical heterogeneity
Assumptions when heterogeneity is estimated
As we expect to include few studies (around two to four) in each
direct comparison, in standard pairwise meta-analysis we will as-
sume a common heterogeneity variance for all direct comparisons.
In network meta-analysis, we will assume a common estimate for
the heterogeneity variance across different comparisons.
Measures and tests for heterogeneity
We will statistically assess the presence of heterogeneity for all
direct pairwise comparisons using common τ 2 and I2 statistics.
Assessment of statistical heterogeneity in the entire networkwill be
based on the magnitude of the heterogeneity variance parameter
(τ 2) estimated by using network meta-analysis models (Jackson
2014).
Assessment of statistical inconsistency
We will assume that any patient who met the inclusion criteria
was, in principle, equally likely to have been randomised to any
of the eligible interventions.
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Local approaches for evaluating inconsistency
To evaluate the presence of inconsistency locally, we will use the
loop-specific approach. We will use this method to evaluate the
consistency assumption in each closed loop of the network sep-
arately as the difference between direct and indirect estimates
for a specific comparison within the loop (inconsistency factor)
(Veroniki 2013). We then can use the magnitude of the inconsis-
tency factors and their 95% CIs to infer the presence of incon-
sistency in each loop. We will assume a common heterogeneity
estimate within each loop and will present the results of this ap-
proach graphically in a forest plot using the ’ifplot’ command in
Stata (Chaimani 2013).
Global approaches for evaluating inconsistency
We will use the ’design-by-treatment’ model to evaluate the as-
sumption of consistency across the entire network (Higgins 2012).
This method accounts for different sources of inconsistency seen
when studies with different designs (two-arm trials vs three-arm
trials) yield different results, as well as disagreement between direct
and indirect evidence. By using this approach, we will infer the
presence of inconsistency from any source in the entire network
on the basis of a Chi2 test. We will perform the design-by-treat-
ment model in Stata using the ’mvmeta’ command. Inconsistency
and heterogeneity are interwoven; to distinguish between these
two sources of variability, we will employ I2 for inconsistency to
measure the percentage of variability that cannot be attributed to
random error or heterogeneity (Jackson 2014).
Subgroup analyses
We will perform subgroup analyses by using the following effect
modifiers as possible sources of inconsistency or heterogeneity, or
both, for each primary outcome.
• Disease course (CIS, RRMS or PPMS/PRMS/SPMS).
• Previous treatment with immunotherapies (no or yes/
possible).
Other sources of heterogeneity
We will take into account the following effect modifiers by per-
forming meta-regression or, if any, by discussing the extent to
which they could alter the results/conclusions of the review.
• Age (mean or, if not provided, median).
• Gender (male vs female).
• Disease duration (mean or, if not provided, median).
Sensitivity analysis
Wewill perform the following sensitivity analyses for each primary
outcome.
• Inclusion of only trials with low risk of attrition bias.
• Exclusion of trials with a total sample size of fewer than 50
randomised participants, to detect potential small study effects.
’Summary of findings’ table
We will present the main results of this review in a ’Summary
of findings’ (SoF) table, according to recommendations pro-
vided in Chapter 11 of the Cochrane Handbook for Systematic Re-
views of Interventions (version 5.1.0) (Schünemann 2011). We
will provide estimates derived from the network meta-analysis
in accordance with methods of the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) Working
Group (GRADE Working Group 2004). For additional details,
see Salanti 2014.
We will include in the SoF table the following outcomes at longest
follow-up for each drug.
• Proportion of participants who had any SAE.
• Proportion of participants who withdrew as the result of
any AE.
• Proportion of participants who had a serious cardiac
disorder.
• Proportion of participants who had a serious infection or
infestation.
• Proportion of participants who had a serious
gastrointestinal disorder.
• Proportion of participants who had a serious hepatobiliary
disorder.
• Proportion of participants who had a serious immune
system disorder.
For each outcome, we will choose two values for the assumed risk
with placebo (i.e. second highest and second lowest placebo group
risks) in the included studies. We will grade the quality of evidence
for each outcome by considering study limitations, indirectness,
inconsistency, imprecision of effect estimates and risk of reporting
bias. According to the software GRADEpro 2008, we will assign
four levels of quality of evidence: high, moderate, low and very
low.
Reporting
We will report results of the review by completing the PRISMA
(PreferredReporting Items for SystematicReviews andMeta-Anal-
yses) harms checklist (Zorzela 2016).
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A P P E N D I C E S
Appendix 1. Keywords for searching the MS Group Register
{interferon\*} OR {interferon beta} OR {beta-1 interferon} OR {beta 1 interferon} OR {interferon beta-1\*} OR {rebif } OR {avonex}
OR {Betaseron} OR {beta-seron} OR {betaferon} OR {beta-IFN-1\*} OR {interferon beta-1\*} OR {Interferon-beta\*} OR {interferon
beta\*} OR {recombinant interferon beta-1\*} OR {beta-1a interferon} OR {beta 1a interferon} OR {interferon beta-1a} OR {beta 1b
interferon} OR {interferon beta1b } OR {IFNb-1b} OR {IFNbeta-1b} OR {interferon beta-1b} OR {novantrone} OR {novantron}
OR {onkotrone} OR {pralifan} OR {mitozantrone} OR {mitoxantrone} OR {copolymer-1} OR {cop-1} OR {copaxone} OR {glati-
ramer acetate} OR {cpx} OR {cop1} OR {copolymer} OR {glatiramer} OR {immunomodulation\*} OR {immunomodulator\*} OR
{immunosuppression} OR {antegren} OR {natalizumab} OR {tysabri} OR {monoclonal antibody*} OR {Antibodies, Monoclonal} OR
{fingolimod} OR {FTY720} OR {FTY 720} OR {fingolimod hydrochloride} OR {FTY-720} OR {2-amino-2-(2-(4-octylphenyl)ethyl)-
1,3-propanediol hydrochloride} OR {Gilenya} OR {sphingosine-fosphate-receptor antagonist} OR {HMR1726} OR {A77 1726} OR
{Leflunomide} OR {Arava} OR {teriflunomide} OR {TFN} OR {teriflunomide-D4} OR {A771726} OR {Dihydroorotate dehydro-
genase (DHODH) inhibitors} OR {(Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide} OR {dimethyl lfumarate}
OR {Fumaderm} OR {FAG 201} OR {FAG201} OR {FAG-201} OR {BG 00012} OR {BG00012} OR {BG-00012} OR {BG 12
compound} OR {BG12 compound} OR {BG-12 compound} OR {BG-12} OR {tecfidera} OR {Nrf2 activator} OR {oral fumarate}
OR {fumaric acid eaters} OR {alemtuzumab} OR {Campath 1G} OR {Campath-1G} OR {Campath-1-G} OR {Campath 1M} OR
{Campath-1M} OR {MabCampath} OR {Schering brand of alemtuzumab} OR {Campath} OR {Berlex brand of alemtuzumab} OR
{Campath 1H} OR {monoclonal antibody Campath-1H} OR {Campath-1H} OR {monoclonal antibody*} OR {Antibodies, Mono-
clonal} OR {lemtrada} OR {daclizumab} OR {antigen} OR {zenapax} OR {dacliximab} OR {monoclonal antibody} OR {monoclonal
antibodies} OR {antigens} OR {Laquinimod} OR {azathioprine} OR {azathioprine} OR {immuran} OR {imuran} OR {imurel} OR
{immunoglobulin\*} OR {intravenous immunoglobulin\*} OR {iV immunoglobulin\*} {intravenous} OR {Intravenous IG} OR {Intra-
venous Antibodies} {ivig} OR {igiv} OR {adrenal cortex hormones} OR {steroid\*} OR {methylprednisolone} OR {prednisolone} OR
{dexamethasone} OR {corticosteroid\*} OR {acth} OR {prednisone} OR {Adrenocorticotropic Hormone} OR {polyethylene glycol-
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interferon-beta-1a} OR {PEG IFN-beta-1a} OR {Pegylated interferon beta-1a} OR {Ocrelizumab} OR {placebo\*} OR {12-Chloro-2’-
deoxyadenosine} OR {2-Chlorodeoxyadenosine} OR {2’-Deoxy-2-chloroadenosine} OR {Leustatin} OR {methotrexate} OR {mexate}
OR {dicesium salt methotrexate} OR {disodium salt methotrexate} OR {sodium salt methotrexate} OR {methotrexate hydrate} OR
{(D)-isomer methotrexate} OR {(DL)-isomer methotrexate} OR {cyclophosphamide} OR {phosphoramide mustard\} OR \{cfx} OR
{cyclophosphane} OR {cytophosphan} OR {Cyclophosphamide Monohydrate} OR {(+-)-Isomer Cyclophosphamide} OR {phospho-
ramide mustards}
C O N T R I B U T I O N S O F A U T H O R S
Concept development - AC, CDG, GF, IT, LLM, LM, MDB.
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